Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | BTK | Q06187 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445009 | 0.88 | MAP4K4 (0.52) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL4445734 | 0.88 | MAP4K4 (0.53) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL10183255 | 0.88 | MAP4K4 (0.48) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL28566874 | 0.87 | HTT (0.54) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL4436879 | 0.87 | MAP4K4 (0.52) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL28572991 | 0.86 | MAP4K4 (0.52) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL4439169 | 0.86 | MAP4K4 (0.52) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL4439875 | 0.85 | MAP4K4 (0.51) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL28567290 | 0.85 | MAP4K4 (0.51) | MAP4K4BTKAURKAPDPK1AURKB | |
| SCHEMBL12068746 | 0.85 | KDM4E (0.55) | CA1KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| WO-2012058176-A1 | NOVEL HETEROARYL-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012036974-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | PDK1, PDPK1, PDK2 | MAP4K4 51/4885BTK 470/4885AURKA 314/4885 |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | PDPK1, PDK1, PDK3 | MAP4K4 83/4885BTK 504/4885AURKA 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.